Drugs / 10E8.4/iMab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05890963 | Nov 2023 → Apr 2026 overdue | HIV infectious disease | David Ho | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 10E8.4/iMab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05890963 ↗ |
| Route | Intramuscular | “10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant...” NCT05890963 ↗ |
| Route | Intravenous | “10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant...” NCT05890963 ↗ |